Lundbeck

A global biopharmaceutical company specialized in neuroscience

Tipo de empresa

Gran empresa


Sector

Medicina / Farmacéutica / Salud


Ubicación

Ottiliavej 9, 2500 Copenhagen, Denmark

Descubrir Lundbeck

Reproducir el vídeo
Imagen de previsualización de vídeo

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience. We discover, develop, and commercialize treatments that improve the lives of people affected by neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

We are 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks, or in the field, we work closely with patients, healthcare professionals, and the neuroscience community to uncover causes, find new treatments, and fight stigma and discrimination against people living with brain diseases.

We build on our Danish heritage and more than 70 years in neuroscience, fostering a culture of collaboration, responsibility, and respect.

For additional information, we encourage you to visit our corporate website www.lundbeck.com and connect with us via LinkedIn.

¿Cómo es trabajar para ellos?

El universo Lundbeck

Reproducir el vídeo
Imagen de previsualización de vídeo

Living with chronic migraine - Hero Campaign

Reproducir el vídeo
Imagen de previsualización de vídeo

Lundbeck - World Mental Health Day 2021

  • Año de creación

    1915

  • Igualdad de género

    46%

    54%

  • Presencia internacional

    50 países

  • Valores

    Patient-driven • Courageous • Ambitious • Passionate

Lundbeck y compromisos de RSE

3 acciones completadas 💚

  • Gender balance targets: min. 40% of underrepresented gender.

  • Reduction in scope 1 and 2 carbon emissions

  • Inclusive redesign of key people processes